Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 2/20 | 0.54 |
| ▸ | MOK | Q9UQ07 | 7/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926846 | 0.89 | MCHR1 (0.65) | ATMKDM4EALDH1A1MEN1LMNA | |
| SCHEMBL2922304 | 0.88 | MCHR1 (0.64) | ATMKDM4EALDH1A1MEN1LMNA | |
| SCHEMBL2926863 | 0.81 | MCHR1 (0.69) | ATMALDH1A1LMNAKMT2AMCHR1 | |
| SCHEMBL2920492 | 0.80 | MCHR1 (0.68) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL2921735 | 0.80 | MCHR1 (0.84) | ALDH1A1MEN1LMNAKMT2AMCHR1 | |
| SCHEMBL2923647 | 0.78 | KDM4E (0.52) | ATMKDM4EALDH1A1MEN1LMNA | |
| SCHEMBL2923190 | 0.77 | MCHR1 (0.64) | SYKMOKMCHR1HTR2C | |
| SCHEMBL2918822 | 0.77 | KDM4E (0.59) | ATMKDM4EALDH1A1MEN1LMNA | |
| SCHEMBL2925099 | 0.76 | KDM4E (0.51) | ATMKDM4EALDH1A1MEN1LMNA | |
| SCHEMBL2925095 | 0.76 | KDM4E (0.51) | ATMKDM4EALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1285651-B1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-6930185-B2 | Melanin-concentrating hormone antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | MCHR1, MC1R, MCHR2 | ATM 2312/4885KDM4E 2403/4885ALDH1A1 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.